Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031824 · ClinicalTrials.gov registry record · Phase 3
Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease
A Phase 3 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 82
- Enrollment target
NCT00031824 is a Phase 3 study that has completed, run by Children's Oncology Group. The registered enrollment target is 82 participants.
The verdict
NCT00031824, a Phase 3 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 82 participants
- Enrollment target
Study Summary
RATIONALE: Hydroxychloroquine may decrease the immune response and be effective in treating chronic graft-versus-host disease. It is not yet known if standard therapy for graft-versus-host disease is more effective with or without hydroxychloroquine. PURPOSE: Randomized phase III trial to compare the effectiveness of standard therapy alone with that of standard therapy plus hydroxychloroquine in treating patients who have newly diagnosed chronic graft-versus-host disease.
Interventions
- DRUG prednisone
- DRUG tacrolimus
- DRUG cyclosporine
- DRUG hydroxychloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2002-04 |
| Est. Completion | 2011-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00031824
The ClinicalTrials.gov registry entry for NCT00031824 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which prednisone is the first listed.
NCT00031824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00031824 about?
NCT00031824 is a clinical study titled "Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease". RATIONALE: Hydroxychloroquine may decrease the immune response and be effective in treating chronic graft-versus-host disease. It is not yet known if standard therapy for graft-versus-host disease is more effective with or without hydroxychloroquine. PURPOSE: Randomized phase III trial to compare t...
What is the current status of trial NCT00031824?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 82 participants. The study started on 2002-04. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00031824?
The interventions under investigation include: prednisone (DRUG), tacrolimus (DRUG), cyclosporine (DRUG), hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT00031824?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.